Download or read book Product Profile written by and published by . This book was released on 1992 with total page 70 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for HIV drug resistance tests in low and middle income countries Africa written by World Health Organization and published by World Health Organization. This book was released on 2023-09-12 with total page 30 pages. Available in PDF, EPUB and Kindle. Book excerpt: HIV-1 drug resistance tests may be useful tools for optimizing ART regimens when used in the context of information about viral load, immune and clinical status, adherence practices and available treatment options. Several types of drug resistance tests are available, either as commercial kits or based on published methods for in-house assays. The target product profile for HIV drug resistance tests in low- and middle-income countries: Africa is designed to guide the development of new HIV drug resistance tests in the era of dolutegravir-based antiretroviral therapy (ART) and to facilitate the evaluation of the suitability of currently available HIV drug resistance tests for specific applications. The target product profiles focus on the new-term future for available ART regimens and their use and anticipates an innovate test that will meet the projected demand.

Download or read book Target product profile for readers of rapid diagnostic tests written by World Health Organization and published by World Health Organization. This book was released on 2023-01-31 with total page 26 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for therapy of uncomplicated enteric fever written by and published by World Health Organization. This book was released on 2020-04-30 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for drugs to manage preterm labour written by World Health Organization and published by World Health Organization. This book was released on 2023-12-04 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt: Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. Preterm newborns that survive are at an increased risk of a number of short- and long-term adverse health outcomes, including chronic lung disease, infections and neurological, visual and auditory disabilities. A number of tocolytic agents are currently in use internationally to slow down or stop the progression of labour. However, none of those has shown substantive improvements in fetal or newborn health outcomes.There is an urgent need for new agents to manage preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to manage preterm labour was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of therapeutic agents for pregnant women experiencing spontaneous preterm labour.

Download or read book Target product profile for drugs to prevent pre eclampsia written by World Health Organization and published by World Health Organization. This book was released on 2023-11-23 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt: TPP for drugs to prevent pre-eclampsia Pre-eclampsia and eclampsia affect 4.6% and 1.4% of pregnant women, respectively. They account for the majority of maternal deaths and stillbirths due to hypertensive disorders of pregnancy. Pre-eclampsia can also negatively affect fetal growth, and increase the risk of preterm birth and fetal death. There is an urgent need to identify new agents to prevent pre-eclampsia. An initial target product profile (TPP) for drugs to prevent pre-eclampsia was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. This WHO TPP describes the key characteristics and desired attributes of preventive agents that should be administered to pregnant women identified as being at increased risk of developing pre-eclampsia, accompanied by monitoring for the development of pre-eclampsia. This TPP outlines minimal and preferred characteristics of a medicine that should: - prevent the development of pre- eclampsia; - have a good safety profile during pregnancy; - be commenced early in pregnancy (before 20 weeks’ gestation) and continued throughout pregnancy and postpartum as required; - be suitable for administration in any health care setting where pregnant women receive antenatal care, including in LMICs.

Download or read book Target product profile for drugs to treat pre eclampsia written by World Health Organization and published by World Health Organization. This book was released on 2023-11-23 with total page 24 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for therapy of diagnosed uncomplicated gonorrhoea written by and published by World Health Organization. This book was released on 2020-04-30 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for drugs to prevent spontaneous preterm birth written by World Health Organization and published by World Health Organization. This book was released on 2023-12-04 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt: Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. There is an urgent need for new agents to prevent preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to prevent spontaneous preterm birth was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of preventive agents that should be administered to pregnant women at increased risk of spontaneous preterm birth. This TPP outlines the minimal and preferred characteristics of a medicine that should: - reduce the likelihood of preterm birth and thus prevent (or mitigate) adverse newborn outcomes due to prematurity; - have an excellent safety profile during pregnancy; - be suitable for prescription or administration by skilled health personnel in any health care setting where pregnant women receive antenatal care, including in LMICs; - be commenced early in pregnancy and can be continued throughout pregnancy, as required.

Download or read book Measles rubella microarray patch MR MAP target product profile written by World Health Organization and published by World Health Organization. This book was released on 2020-03-06 with total page 24 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for therapy of neonatal sepsis in high resistance settings written by and published by World Health Organization. This book was released on 2020-04-30 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for a low cost test for use in bacterial meningitis outbreak response and surveillance written by World Health Organization and published by World Health Organization. This book was released on 2024-04-11 with total page 26 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile to detect prepatent Dracunculus medinensis infections in animals written by World Health Organization and published by World Health Organization. This book was released on 2024-04-03 with total page 21 pages. Available in PDF, EPUB and Kindle. Book excerpt: Dracunculiasis, also known as Guinea-worm disease, is caused by infection with the parasitic nematode Dracunculus medinensis (the Guinea worm). In May 1986, the Thirty-ninth World Health Assembly declared global elimination (i.e. eradication) of dracunculiasis as a goal. The global dracunculiasis eradication campaign, through community-based interventions, has reduced the burden of the disease from an estimated 3.5 million cases per year in 1986 to only 13 human cases and 688 animal infections during 2022. To date, however, there are no validated tests to diagnose pre-patent D. medinensis infection. A critical part of any eradication programme involves reliably identifying infected and exposed definitive hosts. Historically, the diagnosis of Guinea-worm disease was clinical in nature and occurred via visually confirming the emergence of a white worm, roughly 10–14 months after the acquisition of infection. Currently, the definitive diagnosis involves either microscopy or, if necessary, conventional polymerase chain reaction applied to a DNA preparation from emergent worm fragments. A diagnostic tool capable of confirming active infection with D. medinensis many months before the emergence of a Guinea worm would represent a leap forward for the global dracunculiasis eradication campaign. Diagnostic modalities and platforms that can be easily used in locations where Guinea worm is observed or suspected among animal hosts are needed for the early diagnosis of prepatent Guinea worm infection to enhance follow-up and containment of infected hosts. Through the early detection and containment of Guinea worm-infected hosts, these diagnostics would ultimately serve to decrease the amount of parasite available in the environment for onward transmission. Diagnostic tools capable of detecting prepatent infection would enhance disease surveillance and provide national programme staff with additional data to identify transmission hot spots before the emergence of worms in affected areas. Diagnostic tools that can identify hosts with prepatent infection would further inform the targeting and implementation of disease-preventive interventions such as tethering of domesticated animal hosts and treating surface water sources with larvicide. Guinea worm diagnostic tools that could detect prepatent infection would also generate evidence of the absence of Guinea worm infection in definitive hosts, which could help certify countries as free of dracunculiasis transmission and ultimately facilitate the certification of dracunculiasis eradication.

Download or read book Target product profile for next generation drug susceptibility testing at peripheral centres written by and published by World Health Organization. This book was released on 2021-08-09 with total page 52 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first high-priority Target Product Profile (TPPs) for new tuberculosis diagnostics were launched in April 2014. Following advances in the TB diagnostics and treatment pipelines since the release of these TPPs as well as recent updates to WHO TB treatment and diagnostics guidelines, a revision process of this TPP was initiated. The objective of the revision was to steer the R&D pipeline discussions to address current diagnostic gaps, seeking alignment with and patient and population needs.

Download or read book Target product profile for a diagnostic test to confirm visceral leishmaniasis written by World Health Organization and published by World Health Organization. This book was released on 2024-09-04 with total page 18 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for scabies to start and stop mass drug administration written by and published by World Health Organization. This book was released on 2022-03-31 with total page 22 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Target product profile for a diagnostic test to confirm cure of visceral leishmaniasis written by World Health Organization and published by World Health Organization. This book was released on 2024-06-26 with total page 16 pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of the target product profile for a diagnostic test for confirmation of a cure for visceral leishmaniasis is to communicate the minimum and ideal characteristics desired to meet the need for an in vitro, laboratory-based test for confirming or rejecting a successful cure post-treatment.